Sanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments.
Tag Archive for: clinical data
adobe stock photos - Michael Derrer Fuchs Novartis has discontinued development of Lu-NeoB, an experimental radioligand therapy targeting the gastrin-releasing peptide receptor, after early clinical data failed to support further development.
GSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into convincing clinical benefits.
Genmab and AbbVie reported positive phase 3 results for epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), demonstrating a significant improvement in progression-free survival (PFS) compared with R-GemOx.
Abivax has reported additional Phase III maintenance data for obefazimod in ulcerative colitis, giving the French biotech more efficacy and safety evidence to support its planned US regulatory filing later this year.
ProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent private placement that includes existing partner Eli Lilly.
UK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.
Sanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, the latest setback raises fresh questions about whether the Bioverativ pipeline can justify its price tag.
Portuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated Parkinson’s disease. The readout marks a setback for one of the more advanced attempts to turn Parkinson’s genetics into a disease-modifying therapy.
Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.